Review Article
Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors
Table 1
Emetogenic potential of oral antineoplastic agents most used in solid tumors (based on MASCC and ESMO guidelines 2010).
| MASCC and ESMO guidelines 2010 | Degree of emetogenicity (incidence) | Agent |
| High (>90%) | Hexamethylmelamine | Procarbazine |
| Moderate (30–90%) | Cyclophosphamide | Temozolomide | Vinorelbine | Imatinib |
| Low (10–30%) | Capecitabine | Etoposide | Sunitinib | Everolimus | Lapatinib |
| Minimal (<10%) | Methotrexate | Gefitinib | Erlotinib | Sorafenib |
|
|